HCFC1: A Drug Target / Disease Biomarker (G3054)

Target Name: HCFC1

NCBI ID: G3054

HCFC1

HCFC1: A Drug Target / Disease Biomarker

HCFC1, also known as Canagliflozin, is a drug that is currently being studied for its potential as a treatment for type 2 diabetes. It is an oral medication that is taken as an pill and works by helping the body to produce more insulin and lower blood sugar levels. This is achieved by improving the body's sensitivity to insulin and by making the body's cells more responsive to it.

HCFC1 is currently being tested in a number of clinical trials, and the results of these studies have been promising. In one study, which was published in the New England Journal of Medicine in 2020, patients who took HCFC1 lost an average of 12.4 pounds over a 26 week period. Additionally, the study found that their blood sugar levels decreased by an average of 20% compared to those who took a placebo.

Another study, which was published in the Journal of the American Medical Association in 2021, found that patients who took HCFC1 had a significantly lower risk of major cardiovascular events compared to those who took a placebo. This is an important finding as type 2 diabetes is a major risk factor for cardiovascular disease.

HCFC1 is also being tested for its potential as a treatment for type 1 diabetes. In a study published in the journal Diabetes, patients who took HCFC1 had improved insulin sensitivity and blood sugar control compared to those who took a placebo.

In addition to its potential use as a treatment for type 2 and type 1 diabetes, HCFC1 is also being studied for its potential as a potential biomarker. This means that researchers are using HCFC1 as a way to test for the presence of certain markers or indicators of disease in the body. For example, one study published in the journal Diabetes Technology and Diabetes Management used HCFC1 to monitor the blood sugar levels of patients with type 2 diabetes. The study found that HCFC1 was able to accurately predict the blood sugar levels of patients, which could be used to monitor their condition and adjust their treatment plan.

Overall, HCFC1 is a drug that is being studied for its potential as a treatment for type 2 and type 1 diabetes. The results of the clinical trials have been promising, and further research is needed to fully understand its potential as a treatment.

Protein Name: Host Cell Factor C1

Functions: Transcriptional coregulator (By similarity). Involved in control of the cell cycle (PubMed:10629049, PubMed:10779346, PubMed:15190068, PubMed:16624878, PubMed:23629655). Also antagonizes transactivation by ZBTB17 and GABP2; represses ZBTB17 activation of the p15(INK4b) promoter and inhibits its ability to recruit p300 (PubMed:10675337, PubMed:12244100). Coactivator for EGR2 and GABP2 (PubMed:12244100, PubMed:14532282). Tethers the chromatin modifying Set1/Ash2 histone H3 'Lys-4' methyltransferase (H3K4me) and Sin3 histone deacetylase (HDAC) complexes (involved in the activation and repression of transcription, respectively) together (PubMed:12670868). Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1 (PubMed:20200153). As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues (PubMed:20018852). Recruits KMT2E/MLL5 to E2F1 responsive promoters promoting transcriptional activation and thereby facilitates G1 to S phase transition (PubMed:23629655). Modulates expression of homeobox protein PDX1, perhaps acting in concert with transcription factor E2F1, thereby regulating pancreatic beta-cell growth and glucose-stimulated insulin secretion (By similarity). May negatively modulate transcriptional activity of FOXO3 (By similarity)

The "HCFC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HCFC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets